AKARI THERAPEUTICS, PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.185 USD | -0.42% |
|
+1.61% | -62.02% |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 17.64M 1.47B |
|---|---|---|---|---|---|
| Net income 2022 | -17M -1.42B | Net income 2023 | -10M -834M | EV / Sales 2022 | - |
| Net cash position 2022 | 13.25M 1.1B | Net cash position 2023 | 3.84M 321M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-1.65
x | P/E ratio 2023 |
-1.53
x | Employees | 11 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 28.78% |
More Fundamentals
* Assessed data
More news
Latest transcript on Akari Therapeutics, Plc
More recommendations
More press releases
| 1 day | -0.42% | ||
| 1 week | +1.61% | ||
| Current month | -36.46% | ||
| 1 month | -36.29% | ||
| 3 months | -55.28% | ||
| 6 months | -67.08% | ||
| Current year | -62.02% |
1 week
1.13
1.24
1 month
1.081.85
Current year
1.083.30
1 year
1.085.50
3 years
1.0846.40
5 years
1.0884.20
10 years
1.08522.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jacques Suzanne
CEO | Chief Executive Officer | 53 | 28/22/28 |
| Founder | 79 | 01/15/01 | |
Wendy DiCicco
DFI | Director of Finance/CFO | 56 | 19/23/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Donald Williams
BRD | Director/Board Member | 65 | 01/16/01 |
| Founder | 79 | 01/15/01 | |
| Director/Board Member | 61 | 05/23/05 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 1.185 | -0.42% | 10,002 |
| 25/24/25 | 1.19 | 0.00% | 3,902 |
| 24/24/24 | 1.19 | -1.65% | 7,532 |
| 23/24/23 | 1.21 | +2.54% | 4,872 |
| 22/24/22 | 1.18 | +1.18% | 13,919 |
Delayed Quote Nasdaq, April 27, 2024 at 02:00 am IST
More quotes
Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). It is conducting a clinical trial of subcutaneous nomacopan for the treatment of HSCT-TMA in pediatrics. The United States Food and Drug Administration (FDA) has granted Rare Pediatric Disease, Orphan Drug, and Fast Track designations to nomacopan for the treatment of pediatric HSCT-TMA. It is also investigating long-acting PASylated-nomacopan (PAS-nomacopan) for treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) in preclinical studies.
Calendar
| 1st Jan change | Capi. | |
|---|---|---|
| -62.02% | 9.39M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- AKTX Stock
